Thierry Chauche - 28 May 2026 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
01 Jun 2026, 21:16:36 UTC
Prior SEC filing
20 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Elizabeth Rozek, Attorney-in-Fact

Key filing fact

Thierry Chauche filed Form 4 for Sagimet Biosciences Inc. (SGMT) on 01 Jun 2026.

Key facts

  • This page summarizes Thierry Chauche's Form 4 filing for Sagimet Biosciences Inc. (SGMT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 01 Jun 2026, 21:16.

Change

  • Previous filing in this sequence was filed on 20 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001895174 Primary reporting owner

Chauche Thierry

Relationship
Chief Financial Officer
Address
SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO
Signature
/s/ Elizabeth Rozek, Attorney-in-Fact
Signature date
01 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+50,000
Change %
Price
$0.000000*
Shares after
50,000
Date
28 May 2026
Ownership
Direct
Underlying class
Series A Common Stock
Underlying amount
50,000
Exercise price
$7.27
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .